| Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection … TP Lodise, NM Smith, N O’Donnell, AE Eakin, PN Holden, ... Journal of Antimicrobial Chemotherapy 75 (9), 2622-2632, 2020 | 49 | 2020 |
| First penicillin-binding protein occupancy patterns for 15 β-lactams and β-lactamase inhibitors in Mycobacterium abscessus ARM Sayed, NR Shah, KB Basso, M Kamat, Y Jiao, B Moya, DS Sutaria, ... Antimicrobial agents and chemotherapy 65 (1), 10.1128/aac. 01956-20, 2020 | 18 | 2020 |
| Novel cassette assay to quantify the outer membrane permeability of five β-lactams simultaneously in carbapenem-resistant Klebsiella pneumoniae and Enterobacter cloacae TH Kim, X Tao, B Moya, Y Jiao, KB Basso, J Zhou, Y Lang, DS Sutaria, ... MBio 11 (1), 10.1128/mbio. 03189-19, 2020 | 18 | 2020 |
| Combating multidrug‐resistant bacteria by integrating a novel target site penetration and receptor binding assay platform into translational modeling Y Lang, NR Shah, X Tao, SM Reeve, J Zhou, B Moya, ARM Sayed, ... Clinical Pharmacology & Therapeutics 109 (4), 1000-1020, 2021 | 12 | 2021 |
| Mechanistic insights to combating NDM-and CTX-M-coproducing Klebsiella pneumoniae by targeting cell wall synthesis and outer membrane integrity NM Smith, KR Boissonneault, L Chen, V Petraitis, R Petraitiene, X Tao, ... Antimicrobial agents and chemotherapy 66 (9), e00527-22, 2022 | 8 | 2022 |
| Generating Genotype-Specific Aminoglycoside Combinations with Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae Y Huang, K Sokolowski, A Rana, N Singh, J Wang, K Chen, Y Lang, ... Antimicrobial agents and chemotherapy 65 (9), 10.1128/aac. 00692-21, 2021 | 8 | 2021 |
| Combination regimens of favipiravir plus interferon alpha inhibit chikungunya virus replication in clinically relevant human cell lines EJ Franco, X Tao, KC Hanrahan, J Zhou, JB Bulitta, AN Brown Microorganisms 9 (2), 307, 2021 | 7 | 2021 |
| Why molnupiravir fails in hospitalized patients AN Brown, Y Lang, J Zhou, EJ Franco, KC Hanrahan, JB Bulitta, ... Mbio 13 (6), e02916-22, 2022 | 6 | 2022 |
| Simulated intravenous versus inhaled tobramycin with or without intravenous ceftazidime evaluated against hypermutable Pseudomonas aeruginosa via a dynamic biofilm model and … H Bilal, JR Tait, Y Lang, J Zhou, PJ Bergen, AY Peleg, JB Bulitta, A Oliver, ... Antimicrobial Agents and Chemotherapy 66 (3), e02203-21, 2022 | 6 | 2022 |
| Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against Pseudomonas aeruginosa for the … JR Tait, H Bilal, KE Rogers, Y Lang, TH Kim, J Zhou, SC Wallis, JB Bulitta, ... Antibiotics 11 (1), 101, 2022 | 5 | 2022 |
| Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic … AA Agyeman, C López-Causapé, KE Rogers, DD Lucas, S Cortés-Lara, ... International Journal of Antimicrobial Agents 62 (3), 106887, 2023 | 4 | 2023 |
| Ceftolozane-tazobactam against Pseudomonas aeruginosa cystic fibrosis clinical isolates in the hollow-fiber infection model: challenges imposed by hypermutability and … JR Tait, M Harper, S Cortés-Lara, KE Rogers, C López-Causapé, ... Antimicrobial Agents and Chemotherapy 67 (8), e00414-23, 2023 | 3 | 2023 |
| Improved characterization of aminoglycoside penetration into human lung epithelial lining fluid via population pharmacokinetics E Shin, Y Zhang, J Zhou, Y Lang, ARM Sayed, C Werkman, Y Jiao, ... Antimicrobial Agents and Chemotherapy 68 (2), e01393-23, 2024 | 2 | 2024 |
| Comprehensive stability analysis of 13 β-lactams and β-lactamase inhibitors in in vitro media, and novel supplement dosing strategy to mitigate thermal drug … J Zhou, Y Qian, Y Lang, Y Zhang, X Tao, B Moya, ARM Sayed, ... Antimicrobial Agents and Chemotherapy 68 (3), e01399-23, 2024 | | 2024 |
| Population pharmacokinetics of enrofloxacin and florfenicol in the giant danio (Devario aequipinnatus) following oral administration of both antibiotics and bath administration … BS Vorbach, J Zhou, Y Lang, JB Bulitta, RPE Yanong Aquaculture 579, 740222, 2024 | | 2024 |
| Two Steps Forward, One Step Back: Combining the Latest Generation of Antimicrobials with Older Agents to Combat the Next Wave of Antibiotic Resistance BTT Nicholas M. Smith, Hubert C. Chua, Zackery P. Bulman, Katie Rose ... ASM Microbe 2019, 2019 | | 2019 |
| New Combinations against NDM-Producing Klebsiella pneumoniae: A Modeling Approach for Pharmacodynamic Optimization BT Nicholas M. Smith, Hubert C. Chua, Zackery P. Bulman, Raymond Cha, Xun ... ASM Microbe 2019, 2019 | | 2019 |
| Novel outer membrane (OM) permeability assay which can account for a time-dependent release of β-lactamase enzymes by Acinetobacter baumannii for 12 β-lactams BJB Tao X, Zhou J, Lang Y, Kim TH, Moya B, Jiao Y, Sutaria DS, Shah NR ... ASM Microbe 2019, 2019 | | 2019 |
| Comprehensive thermal stability data and optimal supplement dosing schemes for in vitro time-kill experiments with 10 beta-lactams and 3 beta-lactamase inhibitor in Mueller … BJB Qian Y, Tao X, Kim TH, Zhou J, Lang Y, Moya B, Sutaria DS, Jiao Y, Shah NR 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 2019 | | 2019 |
| Outer membrane permeability of 15 beta-lactams in multidrug-resistant Acinetobacter baumannii characterized via LC-MS/MS BJB Tao X, Zhou JQ, Lang YZ, Moya B, Jiao YY, Sutaria DS, Shah NR, Kim TH ... 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 2019 | | 2019 |
